Alphyn’s AB-101 Platform is a single source botanical with multiple bioactive compounds to produce therapeutics with multiple mechanisms of action. This enables our therapeutics to attack an individual disease in multiple ways and attack many different diseases. With the power of our platform, Alphyn is establishing a deep product pipeline of potentially more effective and safer therapeutics for patients suffering from skin diseases with few or sub-optimal treatment options.
Safer, Cost-Efficient, & Faster
Based on AB-101a progress to date, the AB-101 Platform offers the potential for safer products that have the possibility of advancing from the laboratory to the clinic to the patient faster and more cost-efficiently than standard drugs.